CRANFORD, N.J., Nov. 9, 2023
/PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the
"Company") (Nasdaq: CTXR), a biopharmaceutical company developing
and commercializing first-in-class critical care products, today
announced that Chairman and CEO Leonard
Mazur will present at the Sidoti Micro-Cap Virtual
Conference on November 15, 2023.
Conference Details:
Presentation:
|
11:30 am ET, Wednesday, November 15, 2023
|
Location:
|
Virtual
|
1x1
meetings:
|
Open to all
investors; conference registration is required
|
|
|
Webinar:
|
Join live
|
About Citius Pharmaceuticals, Inc.
Citius Pharma is a late-stage biopharmaceutical company
dedicated to the development and commercialization of
first-in-class critical care products, with a focus on oncology,
anti-infectives in adjunct cancer care, unique prescription
products, and stem cell therapies. The Company's diversified
pipeline includes two late-stage product candidates. Mino-Lok®, an
antibiotic lock solution for the treatment of patients with
catheter-related bloodstream infections, is enrolling patients in a
Phase 3 Pivotal superiority trial and was granted Fast Track
designation by the FDA. Citius Pharma is preparing to resubmit the
Biologics License Application for LYMPHIR, a novel IL-2R
immunotherapy for an initial indication in CTCL, in early 2024, and
announced plans to form Citius Oncology, a standalone publicly
traded company with LYMPHIR as its primary asset. LYMPHIR received
orphan drug designation by the FDA for the treatment of CTCL and
PTCL. In addition, at the end of March
2023, Citius Pharma completed enrollment in its Phase
2b trial of CITI-002 (Halo-Lido), a
topical formulation for the relief of hemorrhoids. For more
information, please visit www.citiuspharma.com.
Investor Contact:
Ilanit
Allen
ir@citiuspharma.com
908-967-6677 x113
View original content to download
multimedia:https://www.prnewswire.com/news-releases/citius-pharmaceuticals-to-participate-in-the-sidoti-micro-cap-virtual-conference-on-november-15-2023-301983088.html
SOURCE Citius Pharmaceuticals, Inc.